Liquidia

1. YUTREPIA SPRINT trial start2H 2026YUTREPIA SPRINT trial start, 2H 2026, routine
2. YUTREPIA FDA decision4Q 2026YUTREPIA FDA decision, 4Q 2026, thesis-defining
3. YUTREPIA SSc-RP trial startOct 2026YUTREPIA SSc-RP trial start, Oct 2026, routine
4. Liquidia Corporation corporate updateNov 3, 2026Liquidia Corporation corporate update, Nov 3, 2026, routine
5. UTHR soft-mist inhaler FDA approval2027UTHR soft-mist inhaler FDA approval, 2027, material
6. YUTREPIA UTHR corporate updateJan 2027YUTREPIA UTHR corporate update, Jan 2027, notable
7. YUTREPIA PAH trial start1H 2027YUTREPIA PAH trial start, 1H 2027, routine
8. YUTREPIA SSc-RP readoutFeb 2027YUTREPIA SSc-RP readout, Feb 2027, notable
9. Tyvaso UTHR FDA decisionApr 2027Tyvaso UTHR FDA decision, Apr 2027, material
10. '782 patent expiryMay 14, 2027'782 patent expiry, May 14, 2027, routine
11. Ralinepag UTHR PDUFA dateJun 24, 2027Ralinepag UTHR PDUFA date, Jun 24, 2027, material
12. Tyvaso PPF topline2H 2027Tyvaso PPF topline, 2H 2027, material
13. YUTREPIA trial start2H 2027YUTREPIA trial start, 2H 2027, routine
14. YUTREPIA corporate updateMay 23, 2028YUTREPIA corporate update, May 23, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.